Ignite Creation Date:
2025-12-24 @ 5:40 PM
Ignite Modification Date:
2026-03-18 @ 9:34 AM
Study NCT ID:
NCT00108368
Status:
COMPLETED
Last Update Posted:
2009-01-21
First Post:
2005-04-14
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
The Effects of Risperidone and Olanzapine on Thinking
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D012559', 'term': 'Schizophrenia'}, {'id': 'D011618', 'term': 'Psychotic Disorders'}, {'id': 'D001523', 'term': 'Mental Disorders'}], 'ancestors': [{'id': 'D019967', 'term': 'Schizophrenia Spectrum and Other Psychotic Disorders'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D018967', 'term': 'Risperidone'}, {'id': 'D000077152', 'term': 'Olanzapine'}], 'ancestors': [{'id': 'D011744', 'term': 'Pyrimidinones'}, {'id': 'D011743', 'term': 'Pyrimidines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D001569', 'term': 'Benzodiazepines'}, {'id': 'D001552', 'term': 'Benzazepines'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2003-10'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2007-09', 'completionDateStruct': {'date': '2006-03'}, 'lastUpdateSubmitDate': '2009-01-20', 'studyFirstSubmitDate': '2005-04-14', 'studyFirstSubmitQcDate': '2005-04-14', 'lastUpdatePostDateStruct': {'date': '2009-01-21', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2005-04-15', 'type': 'ESTIMATED'}}, 'conditionsModule': {'keywords': ['schizophrenia', 'cognition', 'antipsychotic medication', 'information processing', 'social cognition', 'Psychotic'], 'conditions': ['Schizophrenia', 'Psychotic Disorders']}, 'referencesModule': {'references': [{'pmid': '22688151', 'type': 'DERIVED', 'citation': 'Sergi M, Green M, Widmark C, Reist C, Erhart S, Braff D, Kee K, Marder S, Mintz J. Social Cognition and Neurocognition: Effects of Risperidone, Olanzapine, and Haloperidol. Am J Psychiatry. 2007 Oct 1;164(10):1585-1592. doi: 10.1176/appi.ajp.2007.06091515.'}, {'pmid': '17898351', 'type': 'DERIVED', 'citation': 'Sergi MJ, Green MF, Widmark C, Reist C, Erhart S, Braff DL, Kee KS, Marder SR, Mintz J. Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol. Am J Psychiatry. 2007 Oct;164(10):1585-92. doi: 10.1176/appi.ajp.2007.06091515.'}]}, 'descriptionModule': {'briefSummary': 'The goal of this research is to find ways to maximize the benefits of antipsychotic medications for cognition.\n\nHypothesis: Risperidone and olanzapine will show greater benefits than conventional medications on assessments of social cognition, particularly affect perception and social perception.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '60 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Diagnosed with schizophrenia disorder by a DSM IV.\n* Competent to sign informed consent\n* No history of poor response to Risperdal and Zyprexa\n* No organic brain disease\n\nExclusion Criteria:\n\n* Mental retardation or any chronic medical illness which results in the patient not being appropriate for a switch to Risperdal or Zyprexa.'}, 'identificationModule': {'nctId': 'NCT00108368', 'briefTitle': 'The Effects of Risperidone and Olanzapine on Thinking', 'organization': {'class': 'FED', 'fullName': 'VA Office of Research and Development'}, 'officialTitle': 'The Cognitive Effects of Risperidone and Olanzapine', 'orgStudyIdInfo': {'id': 'MHBS-057-00S'}}, 'armsInterventionsModule': {'interventions': [{'name': 'Risperidone', 'type': 'DRUG'}, {'name': 'Olanzapine', 'type': 'DRUG'}]}, 'contactsLocationsModule': {'locations': [{'zip': '90073', 'city': 'Los Angeles', 'state': 'California', 'country': 'United States', 'facility': 'VA Greater Los Angeles Healthcare System', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'US Department of Veterans Affairs', 'class': 'FED'}, 'collaborators': [{'name': 'Janssen, LP', 'class': 'INDUSTRY'}]}}}